RAPT Therapeutics Inc. (RAPT) stock soars during current market trading. Stated below is the update
RAPT Therapeutics Inc. (NASDAQ: RAPT) stock gained by 85.46% in the current market trading. RAPT Therapeutics is a clinical-stage immunology-based pharmaceutical business focusing on finding, developing, and promoting oral small molecule medicines for cancer and inflammatory disorders patients with large unmet needs. Important Development RPT193 as monotherapy was found to be effective in 31 patients […]
Insider Selling Report: RAPT Therapeutics Inc. [RAPT]’s Chief Scientific Officer, Brockstedt Dirk G., Sells 2,000 Shares
On Jan. 05, Brockstedt Dirk G. divested U.S. $39,428 in shares of RAPT Therapeutics Inc.. The Chief Scientific Officer sold 2,000 shares at a price per share of $19.71. The transaction decreased this specific insider’s holdings to 17,556 shares worth around $0.36 million at present. H.C. Wainwright launched its RAPT Therapeutics Inc. [RAPT] rating to […]